Premium
Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
Author(s) -
Tripaydonis Anne,
Conyers Rachel,
Elliott David A.
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1311
Subject(s) - pharmacogenomics , cardiotoxicity , anthracycline , induced pluripotent stem cell , medicine , pharmacology , chemotherapy , cancer , biology , genetics , embryonic stem cell , breast cancer , gene
Anthracycline‐induced cardiotoxicity ( ACT ) is a severe adverse drug reaction for a subset of children treated with anthracyclines as part of chemotherapy protocols. The identification of genetic markers associated with increased ACT susceptibility has clinical significance toward improving patient care and our understanding of the molecular mechanisms involved in ACT . Human‐induced pluripotent stem cell–derived cardiomyocytes represent a novel approach to determine the pharmacogenomics of ACT and guide the development of genetic screening tests.